Previous 10 | Next 10 |
Bluebird Bio, Inc. (BLUE) Q2 2021 Earnings Conference Call August 09, 2021, 08:00 AM ET Company Participants Nick Leschly – Chief Executive Officer Elizabeth Pingpank – Direct Investor Relations Andrew Obenshain – President Severe Genetic Diseases Philip Gregory – ...
Tesla (NASDAQ:TSLA) took a turn in the spotlight in midday trading on Monday. A positive analyst comment gave a boost to Elon Musk's electric car company. Earnings remained a key theme in intraday trading as well. ShockWave Medical (NASDAQ:SWAV), BioNTech (NASDAQ:BNTX) and Scientific Games (N...
The following slide deck was published by bluebird bio, Inc. in conjunction with their 2021 Q2 earnings call. For further details see: bluebird bio, Inc. 2021 Q2 - Results - Earnings Call Presentation
Gainers: SCWorx (NASDAQ:WORX) +32%, Liminal BioSciences (NASDAQ:LMNL) +28%, Allied Healthcare Products (NASDAQ:AHPI) +20%, Windtree Therapeutics (NASDAQ:WINT) +17%, NRx Pharmaceuticals (NASDAQ:NRXP) +15%. Losers: Axsome Therapeutics (NASDAQ:AXSM) -42%,&...
- On track to complete planned business separation in 4Q 2021; each company launching with approximately 24 months of runway following separation – - Severe genetic disease (SGD) business to scale back operations in Europe to focus on the U.S. market - - ABECMA ...
AMRX,APD,AVYA,BALY,BHVN,BLUE,BNTX,CEVA,CRNC,DISH,EBIX,ELAN,ENR,EPZM,GOLD,GTES,KOD,RDNT,SGMS,SWAV,SYNH,TGNA,TSN,TTD,USFD,VTRS,VTR For Seeking Alpha's full earnings season calendar, click here. For further details see: Notable earnings before Monday's open
bluebird bio, Inc. (NASDAQ: BLUE) today announced that the Company will report financial results for the second quarter ended June 30, 2021 on Monday, August 9, 2021 and host a conference call to discuss the quarterly update on Monday, August 9, 2021 at 8 a.m. ET. Investors may listen t...
bluebird bio, Inc. (Nasdaq: BLUE) today announced that the Compensation Committee of the Company’s Board of Directors approved inducement grants of stock options to purchase a total of 85,000 shares of common stock and 50,000 restricted stock units (“RSUs”) to a new...
Despite recently getting its third drug approved, Bluebird Bio (NASDAQ: BLUE) only has a $1.7 billion market cap . Will the company overcome its past pricing issues and fly to new highs? And could its lead in sickle cell disease clinical trials translate into massive gains for i...
National Resilience and bluebird bio (BLUE) announce a strategic alliance aimed to accelerate the early research, development and delivery of cell therapies.BLUE shares up 2% premarket at $26.44.As part of the agreement, Resilience will acquire bluebird’s Research Triangle (b...
News, Short Squeeze, Breakout and More Instantly...
The downtrodden biotech space has kicked off the second half of 2022 with a boom. Hard-hit gene-editing and gene therapy companies in particular have started the back half of the year on the right foot. Underscoring this point, Bluebird Bio (NASDAQ: BLUE) stock has already risen by ...
Bluebird Bio 's (NASDAQ: BLUE) stock motored upward above 24% amid an unusually high volume of trading before pulling back to around 13.3% by noon on Tuesday, likely as a result of a short squeeze . More than 34.6% of its floating shares were held short as of June 15, which puts...